Skip to main content

Table 1 Outcomes on individual EQ-5D dimensions by treatment group

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

 

Baseline

Week 13

Week 25

Week 37

Week 49

Week 61

EQ-5D dimensions

ENZA (n = 857), %

PBO (n = 826), %

P value

ENZA (n = 809), %

PBO (n = 624), %

P value

ENZA (n = 746), %

PBO (n = 367), %

P value

ENZA (n = 671), %

PBO (n = 267), %

P value

ENZA (n = 610), %

PBO (n = 176), %

P value

ENZA (n = 523), %

PBO (n = 117), %

P value

Mobility

 Level 1

74.9%

74.7%

0.5940

74.7%

71.3%

0.3197

73.7%

70.8%

0.5823

70.4%

70.3%

0.8183

66.7%

30.9%

0.6454

68.5%

71.8%

0.7640

 Level 2 or 3

25.1%

25.3%

 

25.4%

28.8%

 

26.3%

29.1%

 

29.7%

29.7%

 

33.3%

69.1%

 

31.6%

28.3%

 

Self-care

 Level 1

94.9%

93.8%

0.1726

93.9%

92.0%

0.2253

94.0%

90.6%

0.1034

92.4%

91.7%

0.2849

92.3%

92.0%

0.9186

6.9%

10.2%

0.0619

 Level 2 or 3

5.1%

6.2%

 

6.1%

8.0%

 

6.0%

9.3%

 

7.7%

8.3%

 

7.7%

8.0%

 

93.1%

89.7%

 

Usual Activities

 Level 1

80.1%

80.5%

0.9685

74.9%

69.3%

0.0675

77.9%

71.8%

0.0262

76.2%

76.7%

0.3589

70.8%

71.8%

0.9266

72.7%

69.8%

0.6346

 Level 2 or 3

20.0%

19.5%

 

25.1%

30.6%

 

22.1%

28.2%

 

23.9%

23.4%

 

29.3%

28.2%

 

27.31%

30.2%

 

Pain/Discomfort

 Level 1

55.8%

58.5%

0.4623

56.0%

47.8%

0.0051

59.8%

50.7%

0.0163

56.4%

47.6%

0.0475

52.6%

52.8%

0.6281

52.4%

53.9%

0.4483

 Level 2 or 3

44.3%

41.5%

 

44.1%

52.2%

 

40.3%

49.4%

 

43.5%

52.5%

 

47.5%

47.1%

 

47.6%

46.2%

 

Anxiety/Depression

 Level 1

75.0%

72.9%

0.0690

74.4%

67.6%

0.0060

76.3%

71.0%

0.1610

75.9%

72.9%

0.5023

74.0%

68.8%

0.1762

70.8%

71.8%

0.7396

 Level 2 or 3

25.0%

27.2%

 

25.6%

32.4%

 

23.8%

29.1%

 

24.1%

27.0%

 

26.0%

31.3%

 

29.2%

28.2%

 
  1. ENZA enzalutamide, PBO placebo
  2. Differences refer to the comparison between groups in the percentage of patients with (2 or 3) or without (1) problems in each dimension. They do not take into account whether patients are in level 2 or 3. There were very few patients at level 3 in any dimension, even at 61 weeks. P values refer only to the between-group differences